ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 11, 2010 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Nov 11, 2010
News
Lawmakers Question the Activities of FDA's Puerto Rico Office
By Erik Greb
The US Food and Drug Administration's Puerto Rico district office "may be having difficulty exercising oversight on the numerous pharmaceutical manufacturing facilities on the island," according to Rep. Edolphus Towns (D-NY), chair of the US House of Representatives Committee on Oversight and Government Reform.
Sanofi and Genzyme Still at Odds Over Acquisition
By Stephanie Sutton
Sanofi-aventis (Paris) has asked Genzyme to stand aside and let the shareholders decide on whether an acquisition should take place.
EMA Issues Draft Principles on Postapproval Change Management
By Angie Drakulich
The European Medicines Agency published a draft list of questions and answers on postapproval change-management protocols last week.
Biogen Idec Announces Restructuring Program
By Patricia Van Arnum
The biotechnology company Biogen Idec (Weston, MA) announced last week a major restructuring program that will refocus the company's research and development (R&D) programs, consolidate facilities, and reduce its workforce.
ODT Market to Exceed $13 Billion by 2015
By Stephanie Sutton
The market for orally disintegrating and fast dissolving tablets could exceed revenues of $13 billion by 2015 based on upward global growth trends, according to a report from Technology Catalysts International, a technology transfer and business consulting firm based in Virginia.
Week of Nov. 8, 2010: Company and People Notes: Eli Lilly Acquires Avid Radiopharmaceuticals; EMA Recruiting New Director; and More.
Eli Lilly Acquires Avid Radiopharmaceuticals; EMA Recruiting New Director; and More
Regulatory Roundup: PQRI and FDA present Process Drift Workshop, and More.
PQRI and FDA present Process Drift Workshop, and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here